Novel therapeutics modulating CD38: an unprecedented mechanism of action involving autophagy activation against age-related diseases
ENCEFA, biopharmaceutical company steeming from the French Brain Institute (Pitié Salpêtrière Hospital, Paris), develops biologics that specifically modulate CD38 (epitope-related), a key age-related target, to fight neurodegenerative, auto-immune, and more broadly age-related diseases.
« Making a difference by acting very specifically on CD38,
an age-related target at the crossroad of several biological processes,
to directly regulate cell's autophagy and metabolism, while repressing inflammation: an unprecedented mechanism with the potential
to reinstate health in neurons and immune system »
Chief executive officer, Laurence has more than 15 years of experience in project supervision, consulting, management and SME development. She made the most of her skills in international companies such as DELOITTE. She is always seeking for understanding and improvement.
Chief scientific officer, Damien holds a PhD in Cellular Neuroscience from the Brain and Spine Institute (ICM). Prior to join ENCEFA, Damien worked in a consulting firm specialized in life science, and then in another Biotechnology company as neuroscience project manager for experimental biology.
Chief technology officer, Serge is a biotech engineer. His 13 years of experience in molecule research in neuroscience firstly among Pitié Salpétrière laboratory, then ICM and then ENCEFA are key. He is at the origin of ENCEFA's discovery and has already contributed to 2 molecules in neuroscience that have been clinically tested.
ENCEFA’s team has the support of international experts, top clinicians, industrial experts with high responsibilities and successful startup managers.
Recognized institutions support Encefa: